Search

Biogen Inc

Închisă

SectorSănătate

209.54 -0.26

Rezumat

Modificarea prețului

24h

Curent

Minim

208.04

Maxim

215.29

Indicatori cheie

By Trading Economics

Venit

-639M

-320M

Vânzări

258M

2.7B

P/E

Medie Sector

36.922

57.002

EPS

3.6

Marjă de profit

-11.678

Angajați

7,500

EBITDA

-475M

78M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+12.02% upside

Dividende

By Acuity

Următoarele câștiguri

29 oct. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

754M

31B

Deschiderea anterioară

209.8

Închiderea anterioară

209.54

Sentimentul știrilor

By Acuity

46%

54%

161 / 340 Clasament în Healthcare

Biogen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

13 aug. 2026, 20:06 UTC

News

Wolfe Research upgraded Biogen to Outperform, raising its price target to $300, citing a promising late-stage pipeline and recent acquisition of Apellis Pharmaceuticals.

12 aug. 2026, 23:01 UTC

Biogen shares are lower in after-market trading with no specific news identified. The stock remains above its 20-day moving average.

11 aug. 2026, 23:46 UTC

Biogen Inc shares are modestly higher in after-market trading. No specific news was identified to explain the movement amid broader market focus on economic indicators.

10 aug. 2026, 19:36 UTC

Social Media

Biogen Inc has completed its $1 billion acquisition of RayThera. Shares are trading lower despite the strategic development and potential pipeline enhancement.

7 aug. 2026, 23:16 UTC

Social Media

Biogen Inc completed the acquisition of RayThera, valued at up to $1 billion, but shares are lower in after-market trading.

6 aug. 2026, 23:11 UTC

News

Biogen Inc. has completed its acquisition of RayThera Inc., enhancing its immunology portfolio. Shares are trading lower in after-market hours following a recent decline.

5 aug. 2026, 19:26 UTC

News

Biogen Inc reported second-quarter revenue of $2.74 billion, exceeding estimates. Despite strong results, shares are trading lower amid broader market declines.

4 aug. 2026, 20:02 UTC

News

Mizuho raised its price target on Biogen Inc. to $241, contributing to the stock's upward movement during Tuesday's session.

3 aug. 2026, 23:06 UTC

Biogen Inc. shares are trading higher in after-market hours, supported by stronger-than-expected manufacturing data and positive broader market sentiment.

31 iul. 2026, 21:01 UTC

News

Biogen Inc reported second-quarter revenue of $2.74 billion, exceeding estimates. Shares are higher in after-market trading following the positive results and raised EPS guidance.

30 iul. 2026, 19:39 UTC

Biogen Inc shares are lower in Thursday's session, reaching a low of approximately -2.86% earlier. No specific news was identified to explain the decline.

29 iul. 2026, 22:02 UTC

Biogen Inc shares are higher in after-market hours, maintaining a steady upward trajectory since Wednesday's close and staying above the 20-day moving average.

28 iul. 2026, 22:01 UTC

Biogen Inc shares are higher in after-market hours, though no specific news was identified to explain the movement. The stock remains above its 20-day moving average.

27 iul. 2026, 18:56 UTC

Biogen Inc. shares are lower today amid routine trading fluctuations. Broader market declines are influenced by falling oil prices ahead of the Federal Reserve meeting.

24 iul. 2026, 18:26 UTC

Biogen Inc. shares are higher today, continuing an upward trend since Thursday. The stock's movement appears independent of recent oil price volatility.

22 iul. 2026, 22:01 UTC

Biogen Inc shares are trading higher in after-market hours, reflecting an increase since Wednesday's close amid broader market volatility and rising crude oil prices.

21 iul. 2026, 19:46 UTC

News

BIIB trading higher after Guggenheim raised price target to $280.

20 iul. 2026, 22:06 UTC

Biogen Inc. shares rose slightly in after-market hours, despite broader market pressure from a decline in the Conference Board's leading economic index.

17 iul. 2026, 20:02 UTC

Biogen Inc's shares are lower today, continuing a downward trend since Thursday. The broader market reflects a general decline amid notable sell-offs in technology stocks.

16 iul. 2026, 19:02 UTC

News

Biogen partners with Synapticure to launch a virtual ataxia care program. Shares are higher today, reflecting positive sentiment since Wednesday's close.

15 iul. 2026, 23:36 UTC

Biogen Inc. shares declined in after-market trading, reflecting ongoing weakness amid broader market caution related to geopolitical tensions involving the U.S. and Iran.

14 iul. 2026, 23:41 UTC

Event
News

Biogen Inc shares are higher in after-market trading following positive Phase 2 CELIA study results for diranersen, which targets tau in early Alzheimer's disease.

13 iul. 2026, 23:06 UTC

Social Media
News

Biogen received FDA approval for LEQEMBI IQLIK, a subcutaneous Alzheimer's treatment, boosting shares modestly higher in after-market trading.

10 iul. 2026, 21:01 UTC

Biogen Inc shares declined in after-market trading, reversing an initial uptick and nearing the lower end of their one-month trading range. No specific news was identified.

9 iul. 2026, 23:46 UTC

Biogen Inc shares are trading lower in after-market hours, continuing a trend of five consecutive daily declines without any specific news to explain the movement.

8 iul. 2026, 23:56 UTC

Biogen Inc shares are lower in after-market hours, continuing a trend of four consecutive sessions finishing lower, with no specific news identified for the decline.

7 iul. 2026, 23:31 UTC

Biogen Inc shares are higher in after-market trading following Tuesday's close, amid broader market volatility but stable performance above its 20-day moving average.

6 iul. 2026, 23:56 UTC

Biogen Inc. shares are higher in after-market trading, reflecting a slight upward movement since Monday's close and settling near the upper end of their one-month range.

2 iul. 2026, 22:16 UTC

Biogen Inc shares are lower in after-market hours, reflecting a decline since Thursday's close amid mixed market sentiment and a weaker jobs report.

1 iul. 2026, 20:07 UTC

Event

Biogen Inc. shares are lower as broader market sell-offs raise volatility. Barclays notes vulnerabilities in U.S. equity markets affecting investor sentiment.

Comparație

Modificare preț

Biogen Inc Așteptări

Obiectiv de preț

By TipRanks

12.02% sus

Prognoză pe 12 luni

Medie 235.96 USD  12.02%

Maxim 300 USD

Minim 157 USD

În baza a 29 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBiogen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

29 ratings

19

Cumpărare

9

Păstrare

1

Vânzare

Sentiment

By Acuity

161 / 340 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat